|
Volumn 348, Issue 6231, 2015, Pages 178-180
|
Transatlantic lessons in regulation of mitochondrial replacement therapy
|
Author keywords
[No Author keywords available]
|
Indexed keywords
BIOLOGICAL PRODUCT;
MITOCHONDRIAL DNA;
BIOENGINEERING;
EMBRYO;
INNOVATION;
MITOCHONDRIAL DNA;
MITOCHONDRION;
REGULATORY APPROACH;
BIOETHICS;
CLINICAL TRIAL (TOPIC);
CONSULTATION;
DECISION MAKING;
DISORDERS OF MITOCHONDRIAL FUNCTIONS;
DRUG APPROVAL;
ETHICS;
EXPERIENCE;
GAMETE;
GENE THERAPY;
GERM LINE;
HUMAN;
LAW;
LICENCE;
MITOCHONDRIAL DNA DISORDER;
MITOCHONDRIAL REPLACEMENT THERAPY;
NONHUMAN;
PARENTHOOD;
POLICY;
PRIORITY JOURNAL;
PROGENY;
REVIEW;
SAFETY;
STEM CELL;
SUBSTITUTION THERAPY;
UNITED KINGDOM;
WILD TYPE;
COMPARATIVE STUDY;
FOOD AND DRUG ADMINISTRATION;
GENETICS;
GOVERNMENT REGULATION;
LEGISLATION AND JURISPRUDENCE;
MITOCHONDRIAL DISEASES;
UNITED STATES;
UNITED KINGDOM;
UNITED STATES;
CLINICAL TRIALS AS TOPIC;
DNA, MITOCHONDRIAL;
GENETIC THERAPY;
GOVERNMENT REGULATION;
GREAT BRITAIN;
HUMANS;
MITOCHONDRIAL DISEASES;
PUBLIC POLICY;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
EID: 84927519081
PISSN: 00368075
EISSN: 10959203
Source Type: Journal
DOI: 10.1126/science.aaa8153 Document Type: Review |
Times cited : (34)
|
References (19)
|